Steve Weinstein

Steve brings over 25 years of experience as a CEO, entrepreneur, and venture capitalist investing across biotech, medical device, and digital health innovation.

As Managing Director of the Novartis Venture Fund for twelve years, he was actively engaged in all investment decisions across the $800M global portfolio, managed the medical device/digital practice, and invested in biotech. Prior to Novartis, Steve was on the life science team at Prism Venture Partners, a $1.25B family of funds. He began his venture career as a Kauffman Fellow with Mid-Atlantic Venture Funds, focusing on software startups.

Steve is also an entrepreneur, having served as CEO of a Gregor Diagnostics (prostate cancer diagnostic), interim-CEO of ROX Medical (cardiovascular medical device) and COO of The Microbiome Health Research Institute. He consulted to Genentech Neuroscience Innovation evaluating novel approaches to treating neurological diseases including neuromuscular, precision psychiatry, and drug delivery. Early in his career, Steve was CEO of an industrial business he bought out of bankruptcy and built profitably over five years.

He is a board member of Gregor Diagnostics and Celero Systems (intelligent drug delivery for opioid rescue) and was Chairman of Spectrawave (Cardiovascular Imaging) for five years. He is a member of Product Development Review Council for the Cancer Prevention and Research Institute of Texas (CPRIT), an advisor to the Rockefeller Neuroscience Institute, a member of the Virginia Venture Partners Investment Advisory Board, and served on the Innovation Advisory Board of Mass General Brigham Healthcare (2013-2018).

Steve holds an MBA with distinction from the University of Michigan Business School and a BS in mechanical engineering from Columbia University.